IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

LICITRA, LISA FRANCESCA LINDA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 23.960
NA - Nord America 19.442
AS - Asia 18.535
SA - Sud America 2.037
AF - Africa 368
OC - Oceania 215
Continente sconosciuto - Info sul continente non disponibili 33
Totale 64.590
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 18.611
DE - Germania 10.108
CN - Cina 5.910
SG - Singapore 4.940
GB - Regno Unito 3.802
IT - Italia 3.200
HK - Hong Kong 1.844
BR - Brasile 1.460
RU - Federazione Russa 1.421
VN - Vietnam 1.324
BD - Bangladesh 1.238
FR - Francia 1.107
SE - Svezia 893
IN - India 828
JP - Giappone 690
IE - Irlanda 591
ES - Italia 523
CA - Canada 510
NL - Olanda 434
FI - Finlandia 429
ID - Indonesia 318
KR - Corea 273
TW - Taiwan 234
MX - Messico 208
AU - Australia 201
AR - Argentina 183
TR - Turchia 168
BE - Belgio 162
CH - Svizzera 155
PL - Polonia 148
AT - Austria 145
DK - Danimarca 138
GR - Grecia 124
CO - Colombia 123
EC - Ecuador 99
UA - Ucraina 98
PT - Portogallo 97
IQ - Iraq 87
CI - Costa d'Avorio 86
PH - Filippine 79
TH - Thailandia 77
MY - Malesia 75
HU - Ungheria 74
IL - Israele 74
MA - Marocco 70
ZA - Sudafrica 66
RO - Romania 53
IR - Iran 50
PK - Pakistan 50
CL - Cile 48
SA - Arabia Saudita 46
UZ - Uzbekistan 43
VE - Venezuela 42
CZ - Repubblica Ceca 40
NO - Norvegia 39
EG - Egitto 36
PE - Perù 34
TN - Tunisia 28
JO - Giordania 26
SK - Slovacchia (Repubblica Slovacca) 24
AE - Emirati Arabi Uniti 23
HR - Croazia 23
KE - Kenya 23
RS - Serbia 21
JM - Giamaica 18
SI - Slovenia 18
EU - Europa 17
PY - Paraguay 17
LT - Lituania 16
NP - Nepal 16
UY - Uruguay 16
CR - Costa Rica 13
DO - Repubblica Dominicana 13
NZ - Nuova Zelanda 13
AZ - Azerbaigian 12
BG - Bulgaria 12
BO - Bolivia 12
EE - Estonia 12
CY - Cipro 11
HN - Honduras 11
KZ - Kazakistan 11
LU - Lussemburgo 11
OM - Oman 11
DZ - Algeria 10
PA - Panama 10
SY - Repubblica araba siriana 10
GT - Guatemala 9
MD - Moldavia 9
NI - Nicaragua 9
SC - Seychelles 9
LB - Libano 8
LV - Lettonia 8
NG - Nigeria 8
AL - Albania 7
AM - Armenia 7
AP - ???statistics.table.value.countryCode.AP??? 7
KW - Kuwait 7
TT - Trinidad e Tobago 7
GE - Georgia 6
KG - Kirghizistan 6
Totale 64.471
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 8.843
Southend 3.096
Singapore 2.633
Ashburn 1.692
Dallas 1.596
Hong Kong 1.583
San Jose 1.227
Milan 891
Fairfield 881
Chandler 824
Beijing 756
Seattle 677
Council Bluffs 669
Princeton 657
Wilmington 613
Dublin 582
New York 491
Los Angeles 444
Woodbridge 426
Houston 420
Santa Clara 417
Guangzhou 397
Lauterbourg 373
Redwood City 364
Ho Chi Minh City 359
Nanjing 323
Cambridge 297
Hanoi 296
Shanghai 287
Helsinki 283
Tokyo 281
Buffalo 270
Ann Arbor 266
Moscow 250
Bengaluru 249
Des Moines 249
Rome 223
Jakarta 207
Munich 198
Hefei 194
Seoul 191
São Paulo 180
Jinan 166
Tianjin 160
Chicago 153
Boardman 151
Dearborn 149
Shenyang 133
London 129
Hangzhou 121
Berlin 118
Taipei 110
Shenzhen 109
Columbus 108
Changsha 107
Duncan 107
Cangzhou 106
Toronto 103
Grafing 99
San Diego 98
Madrid 97
Naples 97
The Dalles 96
Nuremberg 95
Amsterdam 93
Nanchang 87
Wuhan 87
Abidjan 85
Phoenix 83
Atlanta 78
Dong Ket 77
Washington 70
Hebei 67
Istanbul 66
Paris 65
Athens 64
Ottawa 62
Zhengzhou 62
Chengdu 61
Rio de Janeiro 60
Montreal 59
Vienna 57
Barcelona 56
Jiaxing 56
Da Nang 52
Mumbai 49
Bologna 48
Florence 48
Philadelphia 48
Brussels 47
Denver 47
Hyderabad 47
Boston 46
Turin 46
Fuzhou 45
Bogotá 44
Buenos Aires 44
Central District 44
Haiphong 44
Warsaw 44
Totale 39.905
Salva come PNG Salva come JPEG
Nome #
Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial 4.586
Lenvatinib-induced renal failure : two first-time case reports and review of literature 1.151
Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up† 931
Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up 711
Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040) 615
Nivolumab for recurrent squamous-cell carcinoma of the head and neck 537
Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations 524
Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study 508
Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer 481
Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial 461
A functional gene expression analysis in epithelial sinonasal cancer : Biology and clinical relevance behind three histological subtypes 446
Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer 445
Predictors of Patient-Reported Dysphagia Following IMRT Plus Chemotherapy in Oropharyngeal Cancer 437
Adenocarcinoma of ethmoid sinus : an occupational disease = Adenocarcinoma dei seni paranasali : una malattia professionale 415
Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor-Expressing Salivary Gland Cancer: A Phase II Trial 414
Ferroptosis-Related Gene Signatures: Prognostic Role in HPV-Positive Oropharyngeal Squamous Cell Carcinoma 407
Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach 391
TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: A randomized phase II EORTC trial 379
ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016 351
Genomics in non-adenoid cystic group of salivary gland cancers: one or more druggable entities? 344
Italian version of the M.D. Anderson Symptom Inventory - €”Head and Neck Module : linguistic validation 334
Benefits and Risks of Machine Learning Decision Support System 331
A multicenter randomized trial for quality of life evaluation by non-invasive intelligent tools during post-curative treatment follow-up for head and neck cancer: Clinical study protocol 327
Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck : efficacy and safety in CheckMate 141 by age 325
Role of IMRT/VMAT-Based Dose and Volume Parameters in Predicting 5-Year Local Control and Survival in Nasopharyngeal Cancer Patients 312
Recommendations for head and neck surgical oncology practice in a setting of acute severe resource constraint during the COVID-19 pandemic : an international consensus 310
Interplay between MRI radiomics and immune gene expression signatures in oral squamous cell carcinoma 294
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) 292
Circulating miR-375 as a novel prognostic marker for metastatic medullary thyroid cancer patients 290
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141) : health-related quality-of-life results from a randomised, phase 3 trial 287
Nivolumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use 287
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study 280
PATIENT VOICES, a project for the integration of the systematic assessment of patient reported outcomes and experiences within a comprehensive cancer center: a protocol for a mixed method feasibility study 275
Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma 274
Tailoring treatment of salivary duct carcinoma (SDC) by liquid biopsy:ARv7 expression in circulating tumor cells 273
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial 267
Immune checkpoint inhibitors and Carbon iON radiotherapy In solid Cancers with stable disease (ICONIC) 266
Modelling radiation‐induced salivary dysfunction during IMRT and chemotherapy for nasopharyngeal cancer patients 261
TP53, P14ARF, P16INK4a and H-ras gene molecular analysis in intestinal-type adenocarcinoma of the nasal cavity and paranasal sinuses 256
Descriptive epidemiology of Kaposi sarcoma in Europe. Report from the RARECARE project 254
Big Data in Head and Neck Cancer 248
Radiotherapy for unresectable sinonasal cancers : dosimetric comparison of intensity modulated radiation therapy with coplanar and non-coplanar volumetric modulated arc therapy 247
Gene Expression Clustering and Selected Head and Neck Cancer Gene Signatures Highlight Risk Probability Differences in Oral Premalignant Lesions 247
Do not throw the baby out with the bathwater : SELECT a personalized, de-escalated lenvatinib schedule allows response in locally advanced DTC while controlling major drug-related bleeding 243
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19805 patients, on behalf of MACH-NC group 242
Dysphagia in head and neck cancer patients treated with radiotherapy and systemic therapies : literature review and consensus 237
Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract 237
Role of pretreatment 18F-FDG PET/CT parameters in predicting outcome of non-endemic EBV DNA-related nasopharyngeal cancer (NPC) patients treated with IMRT and chemotherapy 237
Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer : An Italian validation study 236
Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers : a European consensus position paper 235
PD-L1 Expression in Unresectable Locally Advanced or Metastatic Skin Squamous Cell Carcinoma Treated with Anti-Epidermal Growth Factor Receptor Agents 235
Multivariable model for predicting acute oral mucositis during combined IMRT and chemotherapy for locally advanced nasopharyngeal cancer patients 234
Evidence-based treatment options in recurrent and/or metastatic squamous cell carcinoma of the head and neck 231
The Interplay between Age and Viral Status in EBV-Related Nasopharyngeal and HPV-Related Oropharyngeal Carcinoma Patients 229
Critical analysis of locoregional failures following intensity-modulated radiotherapy for nasopharyngeal carcinoma 229
Baseline mri-radiomics can predict overall survival in non-endemic ebv-related nasopharyngeal carcinoma patients 229
The day after De-ESCALaTE and RTOG 1016 trials results 223
Complete Response to Nivolumab in Recurrent/Metastatic HPV-Positive Head and Neck Squamous Cell Carcinoma Patient After Progressive Multifocal Leukoencephalopathy: A Case Report 223
Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma 222
Tumor Biomarkers for the Prediction of Distant Metastasis in Head and Neck Squamous Cell Carcinoma 222
Are Fusion Transcripts in Relapsed/ Metastatic Head and Neck Cancer Patients Predictive of Response to Anti-EGFR Therapies? 219
A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas : Translational analyses and clinical impact 218
Response of the Istituto Nazionale Tumori of Milan Head & Neck Cancer Unit to the COVID-19 outbreak 218
Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer 217
Transcriptomics and Epigenomics in head and neck cancer: available repositories and molecular signatures 215
T-cell therapy for EBV-associated nasopharyngeal carcinoma : preparative lymphodepleting chemotherapy does not improve clinical results 213
Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma : a phase II trial of 22 patients 213
Phase II study of CC-486 (oral azacitidine) in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma 213
Locally advanced epithelial sinonasal tumors: The impact of multimodal approach 212
Comment on 'Impact of intra-arterial chemotherapy including internal carotid artery for advanced paranasal sinus cancers involving the skull base' 211
Health care-associated infections in patients with head and neck cancer treated with chemotherapy and/or radiotherapy 211
Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis : a randomized, double-blind study 209
HER2 status in recurrent/metastatic androgen receptor overexpressing salivary gland carcinoma patients 208
Hope in cancer patients : The relational domain as a crucial factor 207
The observational clinical registry (cohort design) of the European Reference Network on Rare Adult Solid Cancers: The protocol for the rare head and neck cancers 205
Identification of potentially druggable molecular alterations in skin adnexal malignancies 205
Pain management in head and neck cancer patients undergoing chemo-radiotherapy : Clinical practical recommendations 202
Circulating pre-treatment Epstein-Barr virus DNA as prognostic factor in locally-advanced nasopharyngeal cancer in a nonendemic area 202
Association of a gene-expression subtype to outcome and treatment response in patients with recurrent/ metastatic head and neck squamous cell carcinoma treated with nivolumab 200
Rationale and design of LUX-Head & Neck 1 : a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy 200
Prognostic role of primary tumor, nodal neck, and retropharyngeal GTVs for unresectable sinonasal cancers treated with IMRT and chemotherapy 200
Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Unsuitable to Receive Cisplatin-Based Therapy 200
An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer 198
Activity of platinum and cetuximab in cutaneous squamous cell cancer not amenable to curative treatment 198
Integrative miRNA-Gene expression analysis enables refinement of associated biology and prediction of response to cetuximab in head and neck squamous cell cancer 198
Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study 196
Perspectives in immunotherapy: Meeting report from the "Immunotherapy Bridge", Napoli, November 30th 2016 196
Prevalence of Fatigue in Head and Neck Cancer Survivors 196
Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma 195
An old but still unanswered question in recurrent or metastatic salivary duct carcinoma 195
Head and neck cancer 194
Pan-Asian adaptation of the EHNS–ESMO–ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck 194
Primary chemotherapy followed by anterior craniofacial resection and radiotherapy for paranasal cancer 192
Fentanyl pectin nasal spray as treatment for incident predictable breakthrough pain (BTP) in oral mucositis induced by chemoradiotherapy in head and neck cancer 192
Tumor molecular landscape of Epstein-Barr virus (EBV) related nasopharyngeal carcinoma in EBV-endemic and non-endemic areas: Implications for improving treatment modalities 191
Lung metastasectomy in adenoid cystic cancer : is it worth it? 190
Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: case series and large-scale pharmacovigilance analysis 190
Quality of life in head and neck cancer survivors: the Big Data for Quality of Life study 188
Functional genomics uncover the biology behind the responsiveness of head and neck squamous cell cancer patients to cetuximab 188
Activity and safety of afatinib in a window pre-operative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN) 187
Totale 33.091
Salva come PNG Salva come JPEG
Categoria #
all - tutte 159.337
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 159.337
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021620 0 0 0 0 0 0 0 0 0 0 0 620
2021/20225.336 527 414 392 406 466 364 396 391 469 435 237 839
2022/20234.738 576 359 541 413 429 826 199 246 474 191 272 212
2023/20249.379 200 313 247 268 654 298 1.352 1.202 712 1.228 1.430 1.475
2024/202510.955 1.272 1.711 1.101 1.125 529 412 378 885 553 681 738 1.570
2025/202622.312 1.553 1.037 2.773 1.298 1.915 1.585 2.595 1.493 2.793 1.569 2.456 1.245
Totale 67.626